The AdexusDx human chorionic gonadotropin (hCG) point-of-care test from NowDiagnostics Inc, Springdale, Ark, uses a single drop of capillary or whole blood to diagnose pregnancy earlier than urine-based tests. The test has received FDA premarket notification (510(k)) clearance and is registered under the terms of the Clinical Laboratory Improvement Amendments of 1988. The company’s first FDA-cleared test available in the United States, the test is an immunoassay used for the qualitative detection of hCG in human whole blood, plasma, or serum. Depending on the woman and her pregnancy, the test can detect pregnancy approximately 2 to 8 days earlier than commonly available urine-based tests, according to the company. Results are available 10 minutes after the test is used. For more information, visit NowDiagnostics Inc.